Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aprea Therapeutics Inc (APRE)
NASDAQ:APRE
RESEARCH TOOLSreports
Holding APRE?
Track your performance easily
APRE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.15 - $8.85
Previous Close$2.92
Volume1.66K
Average Volume (3M)22.27K
Market Cap
$15.87M
Enterprise Value-$10.36M
Total Cash (Recent Filing)$26.25M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Mar 27, 2025EPS Estimate
-$0.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.81
Shares Outstanding5,434,903
10 Day Avg. Volume14,651
30 Day Avg. Volume22,266
Standard Deviation0.26
R-Squared0.04
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.74
Price to Sales (P/S)8.73
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-5.51
Enterprise Value/Gross Profit-17.77
Enterprise Value/Ebitda0.76
Forecast
1Y Price Target
$18.00Price Target Upside516.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Aprea Therapeutics News
PremiumCompany Announcements
Aprea Therapeutics Reports Promising Results for APR-1051 Trials
Bulls Say, Bears Say
Bulls Say
Clinical ProgressAPR-1051 recently began enrollment in its Phase 1 ACESOT-1051 study, in patients with advanced solid tumors overexpressing Cyclin E, and other biomarkers predicted to be sensitive to WEE1 inhibition.
Financial StrengthThe company ended the quarter with $28.7 million in cash, which management believes should provide runway for all ongoing operations into 4Q25.
Safety ProfileAPR-1051 is a completely different molecule from other WEE1 inhibitors that have had toxicity issues, and the FDA has permitted the P1 to use continuous dosing based on preclinical data.
Bears Say
Clinical TrialsThe Zentalis molecule, an analogue of an older Merck WEE1 inhibitor, has had significant safety issues and was placed on partial clinical hold.
Drug DevelopmentZentalis Pharmaceuticals announced that its lead synthetic lethality molecule, WEE1 inhibitor ZN-c3 has been placed on partial clinical hold following the deaths of two patients in one of its monotherapy studies.
Pipeline ChallengesZentalis' entire pipeline is centered around the Zn-c3 molecule, which is now facing significant clinical and market challenges.
---
Ownership Overview
12.36% Insiders
2.84% Mutual Funds
31.34% Other Institutional Investors
50.15% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
APRE FAQ
What was Aprea Therapeutics Inc’s price range in the past 12 months?
Aprea Therapeutics Inc lowest stock price was $2.15 and its highest was $8.85 in the past 12 months.
What is Aprea Therapeutics Inc’s market cap?
Currently, no data Available
When is Aprea Therapeutics Inc’s upcoming earnings report date?
Aprea Therapeutics Inc’s upcoming earnings report date is Mar 27, 2025 which is in 125 days.
How were Aprea Therapeutics Inc’s earnings last quarter?
Aprea Therapeutics Inc released its earnings results on Nov 07, 2024. The company reported -$0.64 earnings per share for the quarter, beating the consensus estimate of -$0.716 by $0.076.
Is Aprea Therapeutics Inc overvalued?
According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued.
Does Aprea Therapeutics Inc pay dividends?
Aprea Therapeutics Inc does not currently pay dividends.
What is Aprea Therapeutics Inc’s EPS estimate?
Aprea Therapeutics Inc’s EPS estimate is -$0.66.
How many shares outstanding does Aprea Therapeutics Inc have?
Aprea Therapeutics Inc has 5,434,903 shares outstanding.
What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?
Aprea Therapeutics Inc reported an EPS of -$0.64 in its last earnings report, beating expectations of -$0.716. Following the earnings report the stock price went down -2.451%.
Which hedge fund is a major shareholder of Aprea Therapeutics Inc?
Among the largest hedge funds holding Aprea Therapeutics Inc’s share is Blackstone Inc.. It holds Aprea Therapeutics Inc’s shares valued at N/A.
---
Aprea Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (516.44% Upside)
$18.00 (516.44% Upside)
Hedge Fund Trend
Decreased
By 16.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $136.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.3%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.08%
12-Months-Change
Fundamentals
Return on Equity
-60.22%
Trailing 12-Months
Asset Growth
4.38%
Trailing 12-Months
Company Description
Aprea Therapeutics Inc
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded in 2002 and is headquartered in Boston, MA.
---
APRE Stock 12 Month Forecast
Average Price Target
$18.00
▲(516.44% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
TRACON Pharmaceuticals
―
Crispr Therapeutics AG
―
Meiragtx Holdings
―
Best Analysts Covering APRE
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-25.05%
reiterated a buy rating 5 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -25.05% per trade.
---